Celcuity Inc. (CELC) NASDAQ
91.42
-31.54(-25.65%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
91.42
-31.54(-25.65%)
Currency In USD
| Previous Close | 122.96 |
| Open | 95 |
| Day High | 99.83 |
| Day Low | 89 |
| 52-Week High | 151.02 |
| 52-Week Low | 11.09 |
| Volume | 5.67M |
| Average Volume | 938,892 |
| Market Cap | 4.46B |
| PE | -23.44 |
| EPS | -3.9 |
| Moving Average 50 Days | 123.68 |
| Moving Average 200 Days | 94.9 |
| Change | -31.54 |
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
GlobeNewswire Inc.
Mar 09, 2026 9:42 PM GMT
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively MINNEAPOLI
Celcuity To Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 9:01 PM GMT
MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founde
Celcuity Appoints Charles Romp to its Board of Directors
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of D